These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 34281237)

  • 21. In Silico/In Vitro Hit-to-Lead Methodology Yields SMYD3 Inhibitor That Eliminates Unrestrained Proliferation of Breast Carcinoma Cells.
    Alshiraihi IM; Jarrell DK; Arhouma Z; Hassell KN; Montgomery J; Padilla A; Ibrahim HM; Crans DC; Kato TA; Brown MA
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33333978
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The SMYD3-MAP3K2 signaling axis promotes tumor aggressiveness and metastasis in prostate cancer.
    Ikram S; Rege A; Negesse MY; Casanova AG; Reynoird N; Green EM
    Sci Adv; 2023 Nov; 9(46):eadi5921. PubMed ID: 37976356
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Delineating the active site architecture of G9a lysine methyltransferase through substrate and inhibitor binding mode analysis: a molecular dynamics study.
    Ramya Chandar Charles M; Hsieh HP; Selvaraj Coumar M
    J Biomol Struct Dyn; 2019 Jul; 37(10):2581-2592. PubMed ID: 30047835
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Smyd2 conformational changes in response to p53 binding: role of the C-terminal domain.
    Chandramouli B; Melino G; Chillemi G
    Mol Oncol; 2019 Jun; 13(6):1450-1461. PubMed ID: 31069954
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Proteomic analyses of the SMYD family interactomes identify HSP90 as a novel target for SMYD2.
    Abu-Farha M; Lanouette S; Elisma F; Tremblay V; Butson J; Figeys D; Couture JF
    J Mol Cell Biol; 2011 Oct; 3(5):301-8. PubMed ID: 22028380
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells.
    Hamamoto R; Furukawa Y; Morita M; Iimura Y; Silva FP; Li M; Yagyu R; Nakamura Y
    Nat Cell Biol; 2004 Aug; 6(8):731-40. PubMed ID: 15235609
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhanced methyltransferase activity of SMYD3 by the cleavage of its N-terminal region in human cancer cells.
    Silva FP; Hamamoto R; Kunizaki M; Tsuge M; Nakamura Y; Furukawa Y
    Oncogene; 2008 Apr; 27(19):2686-92. PubMed ID: 17998933
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanism of histone methylation catalyzed by protein lysine methyltransferase SET7/9 and origin of product specificity.
    Guo HB; Guo H
    Proc Natl Acad Sci U S A; 2007 May; 104(21):8797-802. PubMed ID: 17517655
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The dynamic conformational landscape of the protein methyltransferase SETD8.
    Chen S; Wiewiora RP; Meng F; Babault N; Ma A; Yu W; Qian K; Hu H; Zou H; Wang J; Fan S; Blum G; Pittella-Silva F; Beauchamp KA; Tempel W; Jiang H; Chen K; Skene RJ; Zheng YG; Brown PJ; Jin J; Luo C; Chodera JD; Luo M
    Elife; 2019 May; 8():. PubMed ID: 31081496
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Product specificity and mechanism of protein lysine methyltransferases: insights from the histone lysine methyltransferase SET8.
    Zhang X; Bruice TC
    Biochemistry; 2008 Jun; 47(25):6671-7. PubMed ID: 18512960
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Arabidopsis (ASHH2) CW domain binds monomethylated K4 of the histone H3 tail through conformational selection.
    Dobrovolska O; Brilkov M; Madeleine N; Ødegård-Fougner Ø; Strømland Ø; Martin SR; De Marco V; Christodoulou E; Teigen K; Isaksson J; Underhaug J; Reuter N; Aalen RB; Aasland R; Halskau Ø
    FEBS J; 2020 Oct; 287(20):4458-4480. PubMed ID: 32083791
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The telomerase reverse transcriptase (hTERT) gene is a direct target of the histone methyltransferase SMYD3.
    Liu C; Fang X; Ge Z; Jalink M; Kyo S; Björkholm M; Gruber A; Sjöberg J; Xu D
    Cancer Res; 2007 Mar; 67(6):2626-31. PubMed ID: 17363582
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Histone methyltransferase SMYD3 promotes MRTF-A-mediated transactivation of MYL9 and migration of MCF-7 breast cancer cells.
    Luo XG; Zhang CL; Zhao WW; Liu ZP; Liu L; Mu A; Guo S; Wang N; Zhou H; Zhang TC
    Cancer Lett; 2014 Mar; 344(1):129-137. PubMed ID: 24189459
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Smyd3-associated regulatory pathways in cancer.
    Giakountis A; Moulos P; Sarris ME; Hatzis P; Talianidis I
    Semin Cancer Biol; 2017 Feb; 42():70-80. PubMed ID: 27554136
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SMYD3-mediated lysine methylation in the PH domain is critical for activation of AKT1.
    Yoshioka Y; Suzuki T; Matsuo Y; Nakakido M; Tsurita G; Simone C; Watanabe T; Dohmae N; Nakamura Y; Hamamoto R
    Oncotarget; 2016 Nov; 7(46):75023-75037. PubMed ID: 27626683
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of tetrahydrofuranyl spirooxindole-based SMYD3 inhibitors against gastric cancer via inducing lethal autophagy.
    Zhu HP; Chai J; Qin R; Leng HJ; Wen X; Peng C; He G; Han B
    Eur J Med Chem; 2023 Jan; 246():115009. PubMed ID: 36527933
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The lysine 831 of vascular endothelial growth factor receptor 1 is a novel target of methylation by SMYD3.
    Kunizaki M; Hamamoto R; Silva FP; Yamaguchi K; Nagayasu T; Shibuya M; Nakamura Y; Furukawa Y
    Cancer Res; 2007 Nov; 67(22):10759-65. PubMed ID: 18006819
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structural Insights into Stimulation of Ash1L's H3K36 Methyltransferase Activity through Mrg15 Binding.
    Hou P; Huang C; Liu CP; Yang N; Yu T; Yin Y; Zhu B; Xu RM
    Structure; 2019 May; 27(5):837-845.e3. PubMed ID: 30827843
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SMYD3 contributes to a more aggressive phenotype of prostate cancer and targets Cyclin D2 through H4K20me3.
    Vieira FQ; Costa-Pinheiro P; Almeida-Rios D; Graça I; Monteiro-Reis S; Simões-Sousa S; Carneiro I; Sousa EJ; Godinho MI; Baltazar F; Henrique R; Jerónimo C
    Oncotarget; 2015 May; 6(15):13644-57. PubMed ID: 25980436
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ensemble Simulations and Experimental Free Energy Distributions: Evaluation and Characterization of Isoxazole Amides as SMYD3 Inhibitors.
    Wan S; Bhati AP; Wright DW; Wall ID; Graves AP; Green D; Coveney PV
    J Chem Inf Model; 2022 May; 62(10):2561-2570. PubMed ID: 35508076
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.